patent.fyi
Applications  /  US 2026/0355121
United States Patent Application Publication

US 2026/0355121 A1

Published
Nov 12, 2026
Filed
May 8, 2026
Earliest date on the face
May 8, 2025
Classification
A61K 9/5123
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Polymer chains provide stabilization

What ifWhat if a hydrated polymer coating stabilized the lipid particles in water with no lung surfactant present?
Claim language“one or more lung surfactant”

Lipid anchors hold polyethylene glycol chains at the particle surface. The hydrated chains occupy space around each particle and limit close contact during collisions.

1.1Surface charge separates particles

What ifWhat if an ionizable fatty acid supplied repulsion between lipid particles in a model dispersion with no lung surfactant present?
Claim language“one or more lung surfactant”

A fatty acid incorporated at the particle surface loses a proton when the surrounding pH is above its effective acid dissociation point. The exposed carboxylate groups give the particles like charges that repel each other in a low-salt liquid.

1.1Dry sugar matrix stabilization

What ifWhat if a dry sugar matrix kept lipid particles apart during storage with no lung surfactant present?
Claim language“one or more lung surfactant”

Freeze-drying removes water from a suspension containing lipid particles and trehalose. The resulting glassy sugar matrix restricts particle movement during dry storage and dissolves when water is added.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Colloid testing for packaging films

A dispersion of phosphatidylcholine nanoparticles containing synthetic lung surfactant serves as a test fluid for packaging films. A flow cell holds a film coupon flush with one wall and recirculates the dispersion across its exposed face. Light scattering tracks changes in particle size in the circulating fluid, and fluorescence imaging tracks surface deposits from a lipid tracer incorporated into the particles.

Component substitution

Phosphatidylglycerol in place of phosphatidylcholine

Dioleoylphosphatidylglycerol replaces dioleoylphosphatidylcholine as the added lipid in particles containing synthetic lung surfactant. The added lipid and the surfactant lipids form a common film on a glass vessel wall after solvent removal. Hydration with an aqueous buffer followed by membrane extrusion forms a dispersion for measuring particle size and electrophoretic mobility.

Parameter or scale variation

Three size fractions for filtration testing

A hydrated dispersion of lipid nanoparticles containing synthetic lung surfactant is divided into three aliquots of equal volume. Each aliquot passes through a separate membrane extruder with a nominal pore diameter of 50, 100, or 200 nanometers. Dynamic light scattering measures the resulting particle diameters, and a downstream filter test records lipid recovery from each dispersion at the same inlet lipid concentration.

Combination with existing systems

Particle deposition measured by quartz resonator

A flow module delivers lipid nanoparticles containing synthetic lung surfactant across a silica-coated quartz crystal in a quartz crystal microbalance. Buffer establishes the baseline, the particle dispersion flows across the crystal, and a second buffer flow washes the surface. The instrument records frequency and dissipation shifts during exposure and washing to track deposition and retention.

Size separation with inline light scattering

An aqueous dispersion of lipid nanoparticles containing synthetic lung surfactant enters an asymmetric flow field-flow fractionation channel through an injection valve. Crossflow through the channel membrane drives particles toward the accumulation wall, and diffusion separates them by size within the channel flow profile. The outlet feeds a multiangle light-scattering detector and a fraction collector that groups eluate by retention time.

Automated or data-driven variant

Automated measurement of dispersion settling

An automated liquid handler dispenses lipid nanoparticles containing synthetic lung surfactant into a transparent multiwell plate. A motorized camera records transmitted light at two heights in each well at fixed intervals. Software compares the upper and lower intensity traces against buffer wells and reports the time at which a preset intensity difference persists for three consecutive readings.

Specific version of a part

Lipid mixture with defined phospholipids

Dipalmitoylphosphatidylcholine and phosphatidylglycerol form the phospholipid portion of a defined lung surfactant mixture. These phospholipids share a particle bilayer with cholesterol, which occupies space between their hydrocarbon chains.

Lipid mixture with surfactant protein

A lung surfactant mixture contains dipalmitoylphosphatidylcholine and a hydrophobic surfactant protein. Hydrophobic regions of the protein associate with the hydrocarbon region of a phospholipid bilayer.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2008/0019926 A1
Published
Jan 24, 2008
Filed
Apr 18, 2005
Class
A61K 9/12
Document BUS 2021/0121578 A1
Published
Apr 29, 2021
Filed
May 17, 2019
Class
A61K 47/6911
Claim 1
Document A
Document B
1.1one or more lipid component and one or more lung surfactant (Surf-LNP).
In another embodiment, the fluorocarbon may also be administered with a mixture of phospholipids and glycoproteins, such as SP-A, SP-B, SP-C and SP-D, which are components of the native pulmonary surfactant composition.
A · US 2008/0019926 A1 · ¶ 47
The pulmonary surfactant is composed of lipid and membrane protein (Non-Patent Reference, EurRespir J. 1999 June; 13(6):1455-76).
B · US 2021/0121578 A1 · ¶ 5

An empty cell means only that no passage was reproduced there.

Statements in these documents
While RDS is primarily a disease of newborn infants, an adult form of the disease, Adult Respiratory Distress Syndrome (ARDS), has many characteristics in common with RDS, thus lending itself to similar therapies.
A · US 2008/0019926 A1 · ¶ 4
In those pathologies wherein the native lung surfactant is deficient or not functional, molecules of DPPC are immobilized in the form of crystalline islets and cannot re-spread onto the alveolar surface, which can greatly impair the respiratory cycle.
A · US 2008/0019926 A1 · ¶ 7
Cancer patients are increasing significantly every year, and lung cancer patients belong to the category with the highest mortality rate among all cancer patients.
B · US 2021/0121578 A1 · ¶ 3
It is an object of the present invention to provide an anticancer drug that can be efficiently delivered to alveolar cells, has excellent biocompatibility, has low toxicity, and has excellent structural stability.
B · US 2021/0121578 A1 · ¶ 8
Cite aspatent.fyi, US 2026/0355121 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355121/, SHA-256 226da3c3dce5fe41f6b2afea7a63538354b8546bb263e0666ca84ac783b83939
First published
Permanent addresshttps://patent.fyi/US20260355121/
Content fingerprint (SHA-256)226da3c3dce5fe41f6b2afea7a63538354b8546bb263e0666ca84ac783b83939
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi